US biotechnology company Illumina has pledged $ 100 m over a ten - year period to a new , venture capital ( VC ) firm known as Illumina Ventures . This new organisation will share the same values and vision for the future as its parent company , although it will operate independently . Nevertheless , a condition of this investment is Illumina becoming the majority limited partner in the new firm 's first fund . This new VC fund will invest in incubator - based companies that are working on projects dedicated to exploring the future of the human genome . Nicholas Naclerio, Ph.D., Illumina’s former svp, corporate and venture development, has established and will lead Illumina Ventures. Examples of innovative projects include cutting - edge nucleic acid sequencing techniques , products that improve the genomics ecosystem and how this can be utilised to improve health and wellbeing . This fund is the latest in a series where the goal is the expansion of genomics technologies and companies via investment in startups .
US biotechnology company Illumina has pledged $ 100 m over a ten - year period to a new , venture capital ( VC ) firm known as Illumina Ventures . This new organisation will share the same values and vision for the future as its parent company , although it will operate independently . Nevertheless , a condition of this investment is Illumina becoming the majority limited partner in the new firm 's first fund . This new VC fund will invest in incubator - based companies that are working on projects dedicated to exploring the future of the human genome . Examples of innovative projects include cutting - edge nucleic acid sequencing techniques , products that improve the genomics ecosystem and how this can be utilised to improve health and wellbeing . This fund is the latest in a series where the goal is the expansion of genomics technologies and companies via investment in startups .